指南与共识支持与姑息治疗

AGIHO指南:癌症患者COVID-19管理的循证建议——2022年针对奥密克戎变异株的疫苗接种、药物预防与治疗更新

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.
指南 / 共识 · Eur J Cancer · 2022-12-10

该指南由德国血液学与肿瘤内科学会(DGHO)感染性疾病工作组(AGIHO)专家组基于对最新可用数据的批判性审查制定,针对当前占主导的奥密克戎变异株,提供癌症患者COVID-19疫苗接种、药物预防和治疗的循证推荐更新。

要点

  • 指南由DGHO感染性疾病工作组(AGIHO)专家组制定。
  • 基于对最新可用数据的批判性审查提供推荐。
  • 更新内容涵盖疫苗接种、药物预防和治疗。

核心结论

  • 该指南针对当前占主导的奥密克戎变异株,提供癌症患者COVID-19疫苗接种、药物预防和治疗的循证推荐更新。

研究设计与样本

  • 由德国血液学与肿瘤内科学会(DGHO)感染性疾病工作组(AGIHO)专家组基于对最新可用数据的批判性审查制定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Giesen N, Busch E, Schalk E, et al. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. Eur J Cancer. 2022. PMID: 36652889. doi:10.1016/j.ejca.2022.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。